[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nuvalent Inc Cl A (NUVL)

Nuvalent Inc Cl A (NUVL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,272,080
  • Shares Outstanding, K 78,617
  • Annual Sales, $ 0 K
  • Annual Income, $ -425,380 K
  • EBIT $ -439 M
  • EBITDA $ -450 M
  • 60-Month Beta 1.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.86

Options Overview Details

View History
  • Implied Volatility 48.45% (+1.16%)
  • Historical Volatility 29.76%
  • IV Percentile 50%
  • IV Rank 26.87%
  • IV High 84.44% on 10/31/25
  • IV Low 35.23% on 12/31/25
  • Expected Move (DTE 1) 6.22 (5.97%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 2
  • Volume Avg (30-Day) 34
  • Put/Call OI Ratio 1.07
  • Today's Open Interest 1,935
  • Open Int (30-Day) 1,726
  • Expected Range 97.99 to 110.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.50
  • Number of Estimates 7
  • High Estimate $-1.38
  • Low Estimate $-1.78
  • Prior Year $-1.31
  • Growth Rate Est. (year over year) -14.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
97.77 +6.98%
on 05/01/26
109.53 -4.51%
on 04/22/26
-0.42 (-0.40%)
since 04/14/26
3-Month
93.91 +11.38%
on 03/24/26
109.53 -4.51%
on 04/22/26
+3.78 (+3.74%)
since 02/13/26
52-Week
68.64 +52.38%
on 05/15/25
113.01 -7.45%
on 01/22/26
+33.58 (+47.28%)
since 05/14/25

Most Recent Stories

More News
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results

NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC

NUVL : 104.99 (-0.22%)
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinityâ„¢ Platform

Multi-year global collaboration will leverage Guardant’s tissue and liquid biopsy portfolio to support clinical development and companion diagnostic strategies

GH : 97.55 (-0.93%)
NUVL : 104.99 (-0.22%)
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting

Company to also present preliminary data for zidesamtinib in advanced ROS1-positive solid tumors outside of NSCLC from the global ARROS-1 trial

NUVL : 104.99 (-0.22%)
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026

Zidesamtinib demonstrated meaningful clinical activity in subset of TKI pre-treated ROS1-positive NSCLC patients from ARROS-1 trial previously treated with repotrectinib or taletrectinib, including in...

NUVL : 104.99 (-0.22%)
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC

New Drug Application (NDA) based on data in TKI pre-treated patients from the global ALKOVE-1 Phase 1/2 clinical trial

NUVL : 104.99 (-0.22%)
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026

CAMBRIDGE, Mass. , March 17, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...

NUVL : 104.99 (-0.22%)
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results

Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review; PDUFA target action date of September...

NUVL : 104.99 (-0.22%)
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

CAMBRIDGE, Mass. , Feb. 5, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven...

NUVL : 104.99 (-0.22%)
Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones

FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September 18, 2026

NUVL : 104.99 (-0.22%)
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. , Dec. 22, 2025 /PRNewswire/ --  Nuvalent, Inc.  (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating  precisely  targeted therapies for clinically...

NUVL : 104.99 (-0.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nuvalent Inc. is a biopharmaceutical company. It focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. The company's program pipeline includes ROS1-positive and ALK-positive NSCLC. Nuvalent Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 111.83
2nd Resistance Point 109.02
1st Resistance Point 107.12
Last Price 104.99
1st Support Level 102.41
2nd Support Level 99.60
3rd Support Level 97.70

See More

52-Week High 113.01
Last Price 104.99
Fibonacci 61.8% 96.06
Fibonacci 50% 90.83
Fibonacci 38.2% 85.59
52-Week Low 68.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.